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Background: Depression is a common psychiatric disorder worldwide, including in Iran, and 
is estimated to affect 10%–15% of the population. Antidepressant drugs can have multiple side 
effects, so a good choice of drug is important for successful treatment. This study compared the 
efficacy of nortriptyline with that of fluoxetine in the treatment of patients with major depressive 
disorder and assessed related factors, including age, gender, and level of education.
Methods: The study was a double-blind, randomized clinical trial with a six-month follow-up 
period. Participants were 120 patients aged 15–60 years with a diagnosis of major depressive 
disorder based on a psychiatry interview and the Beck depression rating scale, which were 
performed at the beginning, middle, and end of the study. The patients were treated with 
  nortriptyline or fluoxetine. The paired t-test, independent t-test, and the k chi-square test were 
used to analyze the data.
Results: Twenty-three patients dropped out and 97 remained in the trial. Before intervention, 
the mean depression score was 32.85 ± 6.23 in the nortriptyline group and 33.12 ± 6.50 in the 
fluoxetine group. The results of the independent t-test showed a significant difference between 
depression score means before and after treatment in both groups. Changes at the end of the 
trial compared with baseline scores were 13.4 ± 4.68 and 16.96 ± 4.96 for nortriptyline and 
fluoxetine, respectively. Paired t-testing showed a significant difference in the mean depression 
score for both the nortriptyline and fluoxetine groups. Age, gender, and level of education had 
no significant effects on the outcome of treatment in the two groups.
Conclusion: The present study suggests that both nortriptyline and fluoxetine were effective 
in the treatment of depression, but that fluoxetine was more effective than nortriptyline after 3 
and 6 months of treatment.
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Introduction
Depression is a common psychiatric disorder characterized by a number of signs 
and symptoms which may include depressed mood, anhedonia, insomnia, anorexia, 
  difficulty in concentration, and suicidal thought. The lifetime prevalence of the 
  condition in the general population is reported to be 10%–15%, but in women has 
been reported to be up to 25%.1–3 Depression is much more common in women, 
occurring in a ratio of  2:1, and is the leading cause of disease-related disability 
in women.4,5 Mental health patterns in Iran are similar to those in other countries, 
but it seems that the prevalence of mental health disorders in Iran is lower than 
reported elsewhere. A review of the literature shows a prevalence rate for depres-
sion of 4.29% in Iran.6,7
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Treatment of depression includes pharmacotherapy 
and psychotherapy. The common antidepressant drugs 
are tricyclic antidepressants, heterocyclic antidepres-
sants, monoamine oxidase inhibitors, selective serotonin 
reuptake inhibitors (SSRIs), and sympathomimetics.8,9 The 
side effects of SSRI are reported to be nausea, headache, 
anger, weight loss, insomnia, yawning, diarrhea,   weakness, 
fatigue, and dyspepsia. The side effects reported for tricy-
clic antidepressants include drowsiness, anticholinergic 
effects, weight gain, hypotension, tiredness, dullness, and 
  tachycardia. Among the tricyclic antidepressants,   nortriptyline 
is said to have the fewest complications.   Fluoxetine was the 
first of the SSRIs to be introduced onto the US market and 
remains the most commonly used antidepressant agent in 
the US.10–13
There are some controversies about the effectiveness of 
nortriptyline and fluoxetine in the treatment of depression. 
While some studies have shown that nortriptyline is more 
effective than fluoxetine,13–16 others have shown fluoxetine to 
be more effective than nortriptyline.12,17,18 On the other hand, 
some studies have shown that there was no significant differ-
ence between the two drugs,19–21 although some researchers 
believe that there is a significant difference between the two 
drugs depending on age and gender.22 SSRIs are believed 
to be better tolerated and to have a better safety profile than 
the tricyclic antidepressants.20,23,24 The aim of this study 
was to compare the efficacy and patient satisfaction profile 
for nortriptyline with that of fluoxetine in the treatment of 
major depressive disorder and to determine the influence 
of related factors, including gender, age, and educational 
level, on outcome.
Materials and methods
This study was a randomized, double-blind, clinical trial 
with a 6-month follow-up period carried out in 120 patients 
referred to the Shahid Mofatteh Psychiatric Clinic, Yasuj, 
Iran, from 2007 to 2008. The patients were selected by 
convenience sampling and randomized to one of two treat-
ment groups. Twenty-three participants did not complete the 
study as a result of lack of cooperation, not taking the drugs 
regularly, and lack of punctuality. Inclusion criteria were 
being aged 15–60 years and a diagnosis of major depres-
sive disorder on the basis of an interview and the Beck 
depression rating scale. Patients were excluded if they had 
received any antidepressant drug previously, had criteria for 
grief, adjustment disorder, major depressive disorder with 
psychotic features, had concomitant axis II or III disorder, 
a history of bipolar disorder, or schizophrenia. Women were 
excluded if they were pregnant or breast-feeding. Patients 
who did not respond to the drugs within 8 weeks were also 
excluded. This research was approved by the ethics commit-
tee and vice chancellor for research at Yasuj University of 
Medical Sciences. Patients were informed about the survey, 
and written consent was obtained from all participants or 
their legal guardians.
The study data were gathered from interviews with 
participants at the beginning of the study, and by clinical 
examination and using the Beck depression rating scale 
at the beginning, middle, and end of the study. The Beck 
depression inventory was used because it has been local-
ized and validated for Iran. It also has appropriate reliability 
and validity.25,26 Both patients and the evaluating team were 
unaware of treatment allocation.
The patients received nortriptyline or fluoxetine 
  treatment for 6 months. At the end of trial, 23 patients had 
withdrawn and 97 had remained. For the Beck depression 
Table 1 Baseline data for fluoxetine and nortriptyline groups
Nortriptyline  
group
Fluoxetine   
group
Female 25 26
Male 24 22
Age (mean ± standard deviation) 34.5 ± 15.50 35.1 ± 14.80
Mean depression score before  
intervention
32.85 ± 6.23 33.12 ± 6.50
Table 2 Comparison of mean Beck depression scores according to age before and after 3 and 6 months of treatment with fluoxetine 
or nortriptyline
Age, years n Nortriptyline n Fluoxetine
Month 0 Month 3 Month 6 Month 0 Month 3 Month 6
,20 6 31.83 ± 2.11 24.12 ± 3.67 19.30 ± 2.01 5 32.60 ± 2.8 1 19.60 ± 1.96 15.40 ± 2.05
20–30 22 33.40 ± 4.92 23.18 ± 4.10 19.72 ± 4.31 25 33.32 ± 4.21 19.04 ± 3.30 16.20 ± 4.11
30–40 14 32.21 ± 3.83 23.22 ± 3.78 19.50 ± 3.12 12 33.08 ± 3.90 19.91 ± 2.15 16.30 ± 3.27
.40 7 32.31 ± 2.95 23.42 ± 2.90 19.85 ± 1.78 6 32.33 ± 3.01 19.10 ± 1.98 15.60 ± 3.94
All ages 49 32.85 ± 6.23 23.65 ± 4.48 19.71 ± 4.21 48 33.12 ± 6.50 19.37 ± 3.96 16.16 ± 4.02
Note: Analysis of variance P . 0.05.Clinical Pharmacology: Advances and Applications 2012:4 submit your manuscript | www.dovepress.com
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  inventory, a score .10 was considered to be depression, with 
10–19 scored as mild, 20–29 as moderate, 30–39 as partially 
severe, and .40 as severe depression.27,28 All participants 
had a score $30 (severe depression). Nortriptyline up to 
150 mg/day or fluoxetine up to 60 mg/day was used for 
6 months according to the severity of depression. Another 
self-developed questionnaire was used to record the age, 
gender, and educational level of the participants. Educational 
level was divided into four groups, ie, illiterate, primary 
school, high school, and university graduate. For illiterate 
cases, the questions were read out verbally and a complete 
verbal explanation was given.
A questionnaire was developed to measure the patient’s 
satisfaction with their trial medication and any side effects. 
It consisted of 11 items measured on a three-point Likert 
scale (1 = unsatisfied, 2 = fairly satisfied, 3 = satisfied). The 
reliability of the instruments was measured using Cronbach’s 
alpha. The reliability index was good at 8.41. Drug side 
effects were also recorded.
statistical analysis
The paired t-test was used to compare mean Beck test scores 
for each group before and after treatment. The independent 
t-test was used to compare the means of the two groups at 
baseline, and at 3-month and 6-month follow-up. Paired 
t-tests were used to compare mean depression scores at the 
beginning of treatment with those at the 3-month and 6-month 
follow-up. The total score for satisfaction in terms of side 
effects and treatment outcome was estimated, and using cut-
off points of 40 and 60 was converted into qualitative scores 
of satisfied, partially satisfied, and unsatisfied. Fisher’s Exact 
test was then used to calculate the total satisfaction scores 
for the two treatment groups. The results are presented as 
the mean ± standard deviation, and the significance level 
was set at P , 0.05.
Results
There were approximately equal numbers of men and women 
in both treatment groups, and the mean age was 35 years 
(Table 1). Tables 2–4 show that there was no significant 
difference between the two groups with regard to basic demo-
graphic data including age, gender, and educational level. 
The results also indicate that there was no significant differ-
ence between the two groups for mean Beck depression test 
scores before intervention. However, there was a significant 
difference for these scores between the groups after 3 and 
6 months of treatment (Table 5). Both drugs were effective 
in major depression at 3 and 6 months of follow-up, but flu-
oxetine was more effective than nortriptyline (Figure 1). The 
results also indicate that there was a significant difference 
between the groups for mean Beck depression score before 
and after 3 and 6 months of treatment (P , 0.05, Table 5). 
The descriptive statistics shown in Table 5 indicate that the 
changes in mean Beck depression score at the end of the study 
compared with baseline was 16.96 ± 4.96 and 13.14 ± 4.68 
for fluoxetine and nortriptyline, respectively.
Both drugs had side effects, including headache, 
drowsiness, constipation, anorexia, nausea, and vomiting. 
Fluoxetine was significantly correlated with nausea while 
nortriptyline was not. Nortriptyline was significantly cor-
related with headache, dizziness, drowsiness, weakness, 
aggression, and constipation (Table 6). Total satisfaction 
Table 3 Comparison of mean Beck depression scores according to gender before and after 3 and 6 months of treatment with 
fluoxetine or nortriptyline
Gender n Nortriptyline n Fluoxetine
Month 0 Month 3 Month 6 Month 0 Month 3 Month 6
Female 25 33.05 ± 6.68 24.43 ± 5.21 19.90 ± 4.40 26 32.70 ± 6.93 18.93 ± 4.11 16.34 ± 5.01
Male 24 32.63 ± 5.00 23.30 ± 4.17 19.56 ± 3.35 22 33.40 ± 5.81 19.41 ± 3.24 15.90 ± 3.49
All level 49 32.85 ± 6.23 23.65 ± 4.48 19.71 ± 4.21 48 33.12 ± 6.5 19.37 ± 3.96 16.16 ± 4.02
Table 4 Comparison of mean Beck depression scores based on educational level before and after 3 and 6 months of treatment with 
fluoxetine or nortriptyline
Educational level n Nortriptyline n Fluoxetine
Month 0 Month 3 Month 6 Month 0 Month 3 Month 6
not educated 21 33.10 ± 6.99 24.10 ± 4.21 19.90 ± 4.40 20 32.65 ± 2.93 19.03 ± 3.11 16.24 ± 4.01
Low educated 16 32.80 ± 5.00 23.50 ± 4.67 19.06 ± 4.35 17 33.40 ± 2.91 19.91 ± 4.34 15.90 ± 4.29
High educated 12 32.33 ± 5.76 23.31 ± 4.24 19.52 ± 3.97 11 32.90 ± 2.45 19.80 ± 3.99 16.02 ± 3.98
All levels 49 32.85 ± 6.23 23.65 ± 4.48 19.71 ± 4.21 48 33.12 ± 6.50 19.37 ± 3.96 16.16 ± 4.02Clinical Pharmacology: Advances and Applications 2012:4 submit your manuscript | www.dovepress.com
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with the drugs was estimated by patient perception of side 
effects, and the outcomes were compared between the two 
groups. The results indicated the patients were more satisfied 
with fluoxetine than with nortriptyline (Table 7).
Discussion
Depression is a common psychiatric disorder which may 
cause depressed mood, anhedonia, insomnia, anorexia, dif-
ficulty in concentration, and suicidal thought. It can be treated 
by both psychotherapy and pharmacotherapy. Tricyclic 
antidepressants and SSRIs are drugs commonly used in the 
treatment of depression. This study compared the efficacy 
of nortriptyline (a tricyclic antidepressant) and fluoxetine 
(an SSRI) in the treatment of patients with major depres-
sive disorder. Its findings suggest that both nortriptyline 
and fluoxetine were effective, which is in agreement with 
other studies. However, fluoxetine was more effective than 
nortriptyline in the treatment of major depressive disorder, 
and age, gender, and educational level of the patients did not 
have a significant impact on the treatment.
Our results are different from those of previous studies 
reported by Fabre et al, Roose et al, Akhondzadeh et al, and 
Robinson et al.13–16 These reported that nortriptyline was 
more effective than fluoxetine. Roose et al also reported that 
nortriptyline was more effective than fluoxetine in depres-
sion with melancholic features. Our results are also different 
in this respect from the studies reported by Anderson et al, 
Finkel et al, and Song et al, 19–21 Further, unlike Joyce et al, 
who reported that older male melancholic patients had a 
markedly superior response to nortriptyline compared with 
fluoxetine, and that young female melancholic patients had 
a markedly superior response to fluoxetine,22 the results of 
our study showed that fluoxetine is more effective than nor-
triptyline but with no effect of age and gender.
However, the results of our study are similar to those 
of Khade et al, Attari et al, Bhurghri et al, and Anderson 
et al.12,17–19 In our study, fluoxetine was compared with nor-
triptyline, but in the study by Khade et al nortriptyline was 
compared with fluvoxamine (an SSRI), and fluvoxamine was 
reported to be better than nortriptyline.12
In terms of toxicity, it could be argued that both drugs had 
some side effects. In our study fluoxetine was associated with 
nausea, similar to other studies.10–13,23,24 Meanwhile, Khade 
et al and Otsubo et al reported that fluvoxamine was associ-
ated with nausea and Uher et al reported that escitalopram 
was associated with insomnia, diarrhea, and yawning.10,12,24 
In our study, fluoxetine was significantly associated with 
nausea, whereas Bhurghri et al reported that nortriptyline 
was significantly associated with nausea and headache.18 
Our results indicate that nortriptyline was not significantly 
associated with dry mouth, but other studies have found this 
relationship. In our study, nortriptyline was significantly 
associated with headache, dizziness, constipation, drowsi-
ness, weakness, and aggression, which seems to be in line 
with other studies.10–13,23,24 Khade et al reported that drowsi-
ness, tiredness, and dullness were related to this drug, and 
Uher et al further reported that dry mouth, constipation, and 
weight gain were associated with nortriptyline.10,12
Table 5 Mean Beck scores for depressed patients referring to Yasuj Psychiatric Clinic, iran, by time and kind of treatment
Month 0 Month 3 Month 6 Total decrease after 6 months
nortriptyline 32.85 ± 6.23** 23.65 ± 4.48 19.71 ± 4.21 13.14 ± 4.68
Fluoxetine 33.12 ± 6.50 19.37 ± 3.96 16.16 ± 4.02 16.96 ± 4.96
Significance (t-test) P . 0.05 P , 0.05 P , 0.05 –
Note: **Mean ± standard deviation.
Table  6  Mean  percent  frequency  of  treatment-emergent 
adverse events
Significance (χ2 test)
Headache 24 (48.9) 17 (35.4) 0.026
Dizziness 18 (36.7) 8 (16.3) 0.018
Constipation 13 (26.5) 2 (4.2) 0.016
Drowsiness 15 (30.6) 4 (8.3) 0.005
Weakness 25 (51.0) 11 (22.9) 0.01
Dry mouth 1 (2.1) 3 (6.3) 0.17
Aggression 25 (51.0) 4 (8.3) 0.001
Hypersomnia 14 (28.6) 12 (25.0) 0.39
nausea, vomiting 0 (0) 17 (35.4) 0.045
Anorexia 16 (33.3) 17 (35.4) 0.45
Note: All numbers are written as frequency (%).
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Table 7 Satisfaction profile for nortriptyline and fluoxetine in 
depressed patients referred to Yasuj Psychiatry Clinic, iran
Satisfaction Dissatisfied Partially  
satisfied
Satisfied Total
Drug
nortriptyline 9 (18.4) 33 (67.3) 7 (14.3) 49 (100)
Fluoxetine 5 (10.4) 22 (45.8) 21 (43.75) 48 (100)
Notes: χ2 = 15.2; DF = 3; P , 0.012; all numbers are written as frequency (%).
Based on the results of our study, which are consistent 
with those of Finkel et al, Kasper et al, and Otsubo et al,20,23,24 
it could be argued that the patient satisfaction and tolerability 
profiles of fluoxetine are better than those of nortriptyline 
(Table 7). Finally, we can conclude that fluoxetine and 
nortriptyline are effective in major depressive disorder, but 
that fluoxetine was more effective than nortriptyline, and 
age, gender, and educational level did not contribute to the 
efficacy profiles of these drugs.
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